Government Regulators Tighten Oversight of Gene-Therapy Trials

Federal regulators announced steps last week to increase oversight of the safety of gene-therapy trials. The announcement followed the death of 18-year-old Jesse Gelsinger in an experiment at the University of Pennsylvania last year, and findings that researchers underreported serious side effects in other gene-therapy studies.

The changes involve tougher enforcement of existing rules by the Food and Drug Administration and the National Institutes of Health.

Officials from both

Digital or Print Subscription

Already have an account? Log In Now.